List of Excipients in Branded Drug PREVNAR 13

Prevnar 13 Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Prevnar 13 is a 13-valent pneumococcal conjugate vaccine manufactured by Pfizer. Its excipient system is relatively simple: aluminum phosphate adjuvant, sodium chloride, succinic acid buffer, polysorbate 80, and water for injection. The commercial opportunity is not a novel-excipient replacement program. It is concentrated in qualified supply, low-endotoxin materials, analytical control, formulation services, and manufacturing technologies that support follow-on pneumococcal conjugate vaccines.

Prevnar 13’s primary commercial position has weakened as Pfizer’s Prevnar 20, Merck’s Vaxneuvance, and newer higher-valency vaccines have expanded. The product remains relevant in pediatric and international markets where local guidelines, procurement contracts, or regulatory approvals continue to support PCV13 use.

What excipients are used in Prevnar 13?

Prevnar 13 is a preservative-free, liquid, intramuscular vaccine supplied in a 0.5 mL dose. The formulation contains the following excipient and product-support components:

Component	Approximate amount per 0.5 mL dose	Function
Aluminum phosphate	125 micrograms aluminum	Adsorbent and adjuvant
Sodium chloride	4.25 mg	Isotonicity control
Succinic acid	Approximately 295 micrograms	Buffering and pH control
Polysorbate 80	Approximately 100 micrograms	Surfactant and aggregation control
Water for injection	q.s. to 0.5 mL	Vehicle
CRM197 carrier protein	Approximately 34 micrograms	Conjugation carrier, not a conventional excipient
Pneumococcal polysaccharides	Approximately 32 micrograms total	Active antigen components

Each serotype is chemically linked to CRM197. The 13 polysaccharides are from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Serotype 6B is present at approximately twice the individual polysaccharide mass of the other serotypes.[1]

The formulation contains no antimicrobial preservative. This supports single-dose presentation and reduces preservative-related tolerability and regulatory complexity.

How does the Prevnar 13 excipient system work?

The excipient system performs four core functions.

Aluminum phosphate supports antigen presentation

Aluminum phosphate adsorbs the conjugated polysaccharide antigens and functions as the adjuvant. Its performance depends on particle characteristics, phosphate content, surface chemistry, adsorption capacity, and interaction with the conjugated antigens.

For a follow-on product, aluminum phosphate is not a simple commodity input. Relevant quality attributes include:

• Aluminum concentration and speciation
• Phosphate-to-aluminum ratio
• Particle-size distribution
• Surface area and zeta potential
• Endotoxin burden
• Adsorption percentage for each conjugate
• Desorption behavior during storage
• Impact on syringeability and sedimentation

A supplier offering aluminum phosphate for vaccine use must control lot-to-lot variation more tightly than a supplier selling general pharmaceutical-grade aluminum salts.

Succinic acid controls pH

Succinic acid provides buffering in a formulation containing multiple polysaccharide-protein conjugates and an aluminum salt. Buffer capacity must be balanced against aluminum-phosphate chemistry. Excessive changes in pH can alter adsorption, aggregation, protein integrity, and antigen recovery.

The main commercial opportunity is not a new buffer molecule. It is a validated, low-bioburden, low-endotoxin succinic acid supply supported by vaccine-specific impurity profiles and stability data.

Polysorbate 80 limits surface-related aggregation

Polysorbate 80 reduces adsorption of proteinaceous components to manufacturing equipment, vials, syringes, and other interfaces. It also helps control aggregation of CRM197-containing conjugates.

Polysorbate 80 has known degradation pathways, including hydrolysis and oxidation. Those pathways can generate free fatty acids, peroxides, and other degradants. A vaccine-grade supply strategy should therefore include:

• Peroxide and aldehyde control
• Subvisible-particle testing
• Fatty-acid and ester-profile monitoring
• Oxidative-stress stability studies
• Compatibility testing with aluminum phosphate and container systems

This is one of the strongest excipient opportunities in the Prevnar 13-type formulation. The commercial differentiation lies in analytical control and stability performance rather than in replacing polysorbate 80 with an untested surfactant.

Sodium chloride controls tonicity

Sodium chloride supports isotonicity and injection tolerability. It has limited strategic value as a differentiated excipient, but vaccine manufacturers still require pharmaceutical-grade material with controlled bioburden, endotoxin, and particulate levels.

Water for injection is a critical process input

Water for injection affects bioburden, endotoxin, conductivity, total organic carbon, and process consistency. For conjugate vaccines, water-system control is part of the product-quality strategy because the manufacturing process includes multiple aqueous purification, conjugation, dilution, and formulation steps.

What formulation patents protect Prevnar 13?

Prevnar 13 is protected primarily through a combination of antigen composition, conjugation chemistry, manufacturing know-how, and regulatory exclusivity rather than through a single excipient patent.

Potential protection categories include:

Protection category	Relevance to Prevnar 13
Multivalent antigen composition	Covers selected pneumococcal serotypes and combinations
Polysaccharide purification	Controls antigen purity and size distribution
CRM197 conjugation	Protects conjugation methods, linkers, and conjugate quality
Carrier-protein technology	Supports immunogenicity and product consistency
Adjuvant formulation	May cover adsorption and formulation parameters
Stability and container closure	Protects commercial presentation and storage performance
Manufacturing know-how	Often more important than published patent claims

Prevnar 13 was approved in the United States under biologics license application BLA 125324 in 2010.[1] Unlike small-molecule products approved under an NDA, the product is not ordinarily managed through an Orange Book patent-listing and Paragraph IV framework.

The relevant patent estate has included older pneumococcal conjugate vaccine and CRM197 platform patents. Many early platform patents were filed in the late 1990s and early 2000s. Their commercial effect has declined as terms expired. Manufacturing know-how, analytical comparability, trade secrets, regulatory data, and process validation remain practical barriers to competition.

When does Prevnar 13 lose exclusivity?

Prevnar 13’s principal U.S. biologic data exclusivity period has expired. The statutory reference-product exclusivity period for a biologic is generally 12 years from first licensure under the Biologics Price Competition and Innovation Act. For a 2010 approval, the base period ended in 2022, subject to any applicable pediatric extension.[2]

Exclusivity expiration does not create an automatic generic launch. Vaccines are complex biologics. A competitor must establish manufacturing consistency, analytical comparability, clinical immunogenicity, safety, and regulatory acceptability.

The practical protection profile is therefore:

Asset	Current commercial relevance
U.S. biologic data exclusivity	Expired
Traditional small-molecule generic pathway	Not applicable
Orange Book patents	Generally not applicable
Vaccine composition patents	Dependent on individual patent term and claim scope
Manufacturing process patents	Variable; many early patents have expired
Trade secrets and know-how	Material continuing barrier
Regulatory comparability package	High barrier
Pediatric and national procurement position	Market-dependent

What is the FDA regulatory status of Prevnar 13?

Prevnar 13 is an FDA-approved pneumococcal conjugate vaccine for pediatric and adult populations. The product is supplied as a liquid suspension for intramuscular administration in prefilled syringes and single-dose vials.[1]

The U.S. competitive landscape has changed materially:

Product	Manufacturer	Valency	U.S. position
Prevnar 13	Pfizer	13	Legacy PCV13 product
Vaxneuvance	Merck	15	Approved pediatric and adult PCV
Prevnar 20	Pfizer	20	Higher-valency successor product
Capvaxive	Merck	21	Approved for specified adult use

CDC recommendations have increasingly favored PCV15 or PCV20 for adults and higher-valency products for pediatric vaccination as approvals expanded.[3] This reduces the strategic value of a direct Prevnar 13 replacement in the U.S., while preserving demand in countries that continue to use PCV13 through national immunization programs or procurement tenders.

What commercial opportunities exist for Prevnar 13 excipients?

Qualified aluminum phosphate supply

Aluminum phosphate is the highest-value conventional excipient in the formulation. Suppliers can compete through:

• Vaccine-specific regulatory dossiers
• Multiple qualified manufacturing sites
• Tight particle and adsorption controls
• Low-endotoxin production
• Long-term supply agreements
• Local production for government tenders

The strongest opportunity is dual sourcing. Vaccine manufacturers place a premium on continuity because changing aluminum-phosphate lots can trigger adsorption, stability, and comparability work.

Vaccine-grade polysorbate 80

Polysorbate 80 suppliers can create value through oxidation-resistant grades, tighter peroxide specifications, and validated storage controls. A supplier with robust degradant analytics can support both legacy PCV13 products and newer conjugate vaccines.

Excipient characterization services

Analytical service providers can support:

• Aluminum adsorption assays
• Polysorbate degradation testing
• Particle-size and morphology analysis
• Antigen recovery testing
• CRM197 integrity assessment
• Serotype-specific conjugate quantification
• Stability-indicating methods

These services are relevant to both originator lifecycle management and follow-on vaccine development.

Formulation and process-development partnerships

A development partner can offer formulation screening around:

• Aluminum-phosphate concentration
• Buffer identity and capacity
• Polysorbate concentration
• Antigen-to-adjuvant ratio
• Mixing order
• Hold times
• Container-contact materials
• Shipping and vibration stability

The opportunity is strongest for manufacturers developing PCV15, PCV20, PCV21, or regional multivalent vaccines rather than for direct substitution of Prevnar 13.

Alternative presentation systems

Prevnar 13 is a liquid, refrigerated product. Commercial opportunities include:

• Low-dead-volume prefilled syringes
• Autoinjector-compatible presentations
• Multi-dose formats for public-health programs
• Cold-chain monitoring
• Improved container closure systems
• Stabilized liquid formulations with extended excursion tolerance

Lyophilization is technically possible for some vaccine platforms but would require extensive requalification because drying can change conjugate structure, aluminum adsorption, reconstitution behavior, and immunogenicity.

How strong is the Prevnar 13 patent estate?

The patent estate is moderate as a historical platform estate but weaker as a current stand-alone barrier to competition.

Its strongest elements are likely to be:

1. Complex multivalent conjugate manufacture.
2. Serotype-specific purification and conjugation control.
3. CRM197 production and coupling processes.
4. Analytical release methods.
5. Product-specific stability and formulation know-how.

Its weaker elements are:

1. Basic sodium chloride use.
2. Basic succinic acid buffering.
3. General use of polysorbate 80.
4. Conventional aluminum-phosphate adjuvant use.
5. Broad early platform claims whose terms have expired.

The commercial moat is therefore operational rather than excipient-patent driven. A competitor may be able to purchase the same excipients but still fail to reproduce conjugate quality, adsorption behavior, immunogenicity, and batch consistency.

Are there Paragraph IV challenges to Prevnar 13?

A conventional Paragraph IV challenge is not the expected pathway because Prevnar 13 is licensed as a biologic under a BLA rather than approved as a small molecule under an NDA. The BPCIA provides the relevant framework for biosimilar applications, including reference-product exclusivity and patent-exchange procedures.[2]

No widely established U.S. biosimilar or interchangeable product has displaced Prevnar 13. A follow-on pneumococcal conjugate vaccine would face a more complex regulatory assessment than a conventional generic because serotype composition, conjugation chemistry, carrier protein, adjuvant interaction, and immunogenicity all affect product performance.

What generic entry risks exist for Prevnar 13?

The near-term risk is product substitution by higher-valency vaccines, not a classic generic launch.

Entry scenario	Probability profile	Commercial impact
Direct PCV13 biosimilar	Low to moderate	Could pressure price in selected markets
Higher-valency PCV replacement	High	Erodes routine PCV13 demand
Local or regional PCV13 competitor	Moderate	Relevant in tender markets
Excipient supplier substitution	High	Creates sourcing opportunities but requires qualification
New delivery presentation	Moderate	May improve procurement economics
Manufacturing partnership	Moderate to high	Supports emerging-market access

For Pfizer, the principal defense is migration to Prevnar 20 and broader franchise coverage. For suppliers, the best opportunity is to sell into the entire pneumococcal conjugate vaccine category rather than depend on Prevnar 13 alone.

How does Prevnar 13 compare with newer pneumococcal vaccines?

Prevnar 13 has a mature formulation and extensive clinical-use history. Newer products have a wider serotype range and are positioned to simplify adult vaccination schedules.

Attribute	Prevnar 13	Prevnar 20	Vaxneuvance	Capvaxive
Manufacturer	Pfizer	Pfizer	Merck	Merck
Serotype coverage	13	20	15	21
Core platform	Conjugate vaccine	Conjugate vaccine	Conjugate vaccine	Conjugate vaccine
Excipient opportunity	Mature, limited differentiation	Broad platform reuse	Newer formulation and supply needs	Newer formulation and supply needs
Main commercial issue	Legacy product erosion	Franchise expansion	Competitive differentiation	Adult serotype coverage

From an excipient perspective, the best platform strategy is to qualify materials across multiple pneumococcal conjugate products. A supplier that qualifies aluminum phosphate, polysorbate 80, buffers, and container systems for only Prevnar 13 faces declining volume risk.

What licensing deals and manufacturing partnerships matter?

The most relevant transactions are likely to involve:

• CRM197 or carrier-protein licensing
• Serotype-specific polysaccharide technology
• Conjugation chemistry
• Aluminum adjuvant supply
• Regional fill-finish
• Government procurement
• Technology transfer to local vaccine manufacturers

Excipient companies should prioritize master supply agreements and platform qualification over product-specific exclusivity. A contract tied only to Prevnar 13 has limited growth potential compared with a contract covering Prevnar 13, PCV15, PCV20, PCV21, and future regional formulations.

Key Takeaways

• Prevnar 13 uses aluminum phosphate, sodium chloride, succinic acid, polysorbate 80, and water for injection.
• Aluminum phosphate and polysorbate 80 offer the strongest excipient-related commercial opportunities.
• The product’s biologic exclusivity has expired, but complex manufacturing and regulatory comparability remain substantial barriers.
• A Paragraph IV challenge is not the normal pathway because Prevnar 13 is a BLA-licensed biologic.
• The main competitive threat is substitution by higher-valency vaccines, not a conventional generic.
• Excipient suppliers should target the broader pneumococcal conjugate vaccine platform rather than Prevnar 13 alone.
• Key opportunities include dual sourcing, vaccine-grade aluminum phosphate, oxidation-controlled polysorbate 80, analytical testing, fill-finish, and cold-chain optimization.

FAQs About Prevnar 13 Excipients and Commercial Strategy

Does Prevnar 13 contain a preservative?

No. Prevnar 13 is supplied as a preservative-free, single-dose vaccine.

Is CRM197 an excipient in Prevnar 13?

CRM197 is a carrier protein chemically linked to the pneumococcal polysaccharides. It is a functional component of the conjugate antigen rather than a conventional formulation excipient.

Which Prevnar 13 excipient has the highest sourcing value?

Aluminum phosphate has the highest strategic value because its physical and chemical properties directly affect antigen adsorption, stability, release testing, and immunogenicity.

Can polysorbate 80 in Prevnar 13 be replaced easily?

No. A replacement would require formulation, stability, immunogenicity, container compatibility, and regulatory comparability work.

Is Prevnar 13 still commercially relevant after Prevnar 20?

Yes, but its role is increasingly regional and legacy-oriented. Demand remains where PCV13 is included in national schedules, tenders, or local regulatory approvals, while U.S. growth has shifted toward higher-valency products.

References

1. U.S. Food and Drug Administration. (2024). Prevnar 13 prescribing information. Pfizer Inc.
2. U.S. Food and Drug Administration. (2023). Purple Book: Database of licensed biological products.
3. Centers for Disease Control and Prevention. (2024). Pneumococcal vaccination: Recommendations of the Advisory Committee on Immunization Practices.
4. Pfizer Inc. (2024). 2023 annual report.
5. World Health Organization. (2022). Manual for the laboratory diagnosis of pneumococcal disease.
6. U.S. Pharmacopeia. (2024). General chapters for biological products, vaccine quality, and excipient control.